/
Neurology
Muscular Dystrophy
49
Pipeline Programs↗
78
Active Trials↗
48
Companies Involved↗
Muscular Dystrophy is a moderately active landscape with 49 programs across 48 companies. The most active players are Italfarmaco, Sarepta Therapeutics, Amgen. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical19
Phase 14
Phase 213
Phase 313
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
28 of 33 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 86% of 49 pipeline programs.
Analysis
Trial Status
262
clinical trials
Completed115 · 44%
Terminated42 · 16%
Active, not recruiting34 · 13%
Recruiting30 · 11%
Withdrawn12 · 5%
Not yet recruiting10 · 4%
Other19 · 7%
Clinical Trials
Trial Activity
262 trials
Investigational Use of Neuromuscular Ultrasound
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT05237973·150 enrolled
Phase-2 Trial of 5mg/kg/Week Prednisolone in Young Boys With DMD
Recruiting·—·Approved·NCT05412394·26 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)